In line with Kancera's strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of...
Read MoreROR-1, target for the Kancera treatment for chronic lymphatic leukemia, has been identified on the surface of eight additional blood cancers. Accordingly, medical use of the Kancera candidate drug under development may be expanded within the frames of current...
Read MoreKancera AB (publ) announces that the acquisition of iNovacia AB has been implemented
Read MoreKancera AB has in collaboration with Sprint Bioscience AB, Stockholm, solved the 3- dimensional crystal structure of a novel chemical class in complex with the target enzyme PFKFB3, by conducting experiments at the European Synchrotron Radiation Facility in Grenoble....
Read MoreKancera AB has discovered compounds that kill Chronic Lymphocytic Leukemia (CLL) 25 times more selectively than cytostatic drugs currently used for treating the disease.
Read MoreKancera AB (publ) is carrying out a new share issue, will be listed on First North, and is acquiring the research company iNovacia AB - thereby creating an international and highly competitive cancer drug company.
Read More